文献速递造血干细胞移植与细胞治疗

巨细胞病毒再激活对造血干细胞移植后非复发死亡率的异质性影响

Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation.
PubMed 文献 · Blood Adv · 2020-01-01

研究发现CMV再激活在低、中、高危再激活风险组均显著增加3年NRM,且CML、良好体能状态、HLA相合供者及标危疾病与NRM增加相关。在测试队列中,具有2-4个因素的患者CMV再激活显著增加3年NRM,而0-1个因素者无显著差异。

要点

  • CMV再激活在低、中、高危再激活风险组均显著增加3年NRM。
  • CML、良好PS、HLA相合供者及标危疾病与CMV再激活后NRM增加相关。
  • 具有2-4个上述因素的患者CMV再激活显著增加3年NRM。

核心结论

  • CMV再激活在低、中、高危再激活风险组均显著增加3年NRM。
  • 具有2-4个特定因素的患者CMV再激活显著增加3年NRM,而0-1个因素者无显著差异。

研究设计与样本

  • 采用多因素分析识别CMV再激活危险因素并建立评分模型。
  • 生存分析考虑竞争风险、时依协变量及交互项,在训练队列和测试队列中探索异质性影响。

主要发现

  • 评分模型将再激活风险分为3组,再激活率分别为43.7%、60.9%、71.5%(P<.001)。
  • 3年NRM在CMV再激活患者中显著更高:低危组20.9% vs 13.0%(P<.001),中危组21.4% vs 15.6%(P<.001),高危组29.3% vs 18.0%(P<.001)。
  • 训练队列中,CML(HR 1.76;95%CI 1.05-2.96;P=.033)、良好PS(HR 1.42;95%CI 1.04-1.94;P=.028)、HLA相合供者(HR 1.34;95%CI 1.06-1.70;P=.013)、标危疾病(HR 1.28;95%CI 1.04-1.58;P=.022)与NRM增加相关。
  • 测试队列中,具有2-4个因素的患者CMV再激活显著增加3年NRM(22.1% vs 13.1%;P<.001),而0或1个因素者无显著差异(23.2% vs 20.4%;P=.62)。

临床怎么用

  • CMV预防策略应基于再激活风险评分及其他因素(如CML、良好PS、HLA相合供者、标危疾病)综合决定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytomegalovirus (CMV) infection is a major complication in allogeneic stem cell transplantation. The utility of CMV prophylaxis with letermovir has been reported; however, the specific applications remain unclear. In this study, we retrospectively analyzed large-scale registry data (N = 10 480) to clarify the risk factors for nonrelapse mortality (NRM) in connection with CMV reactivation. First, we identified risk factors for CMV reactivation using multivariate analysis and developed a scoring model. Although the model effectively stratified reactivation risk into 3 groups (43.7% vs 60.9% vs 71.5%; P < .001), the 3-year NRM was significantly higher in patients with CMV reactivation, even in the low (20.9% vs 13.0%, P < .001), intermediate (21.4% vs 15.6%; P < .001), and high (29.3% vs 18.0%; P < .001) reactivation risk groups. Next, survival analysis considering competing risks, time-dependent covariates, and interaction terms for exploring the heterogeneous impact of CMV reactivation on NRM in the training cohort revealed that chronic myeloid leukemia (CML) (hazard ratio [HR], 1.76; 95% confidence interval [CI], 1.05-2.96; P = .033), good performance status (PS) (HR, 1.42; 95% CI, 1.04-1.94; P = .028), HLA-matched donor (HR, 1.34; 95% CI, 1.06-1.70; P = .013), and standard-risk disease (HR, 1.28; 95% CI, 1.04-1.58; P = .022) were associated with increased NRM. In the test cohort, CMV reactivation was significantly associated with increased 3-year NRM among patients with 2 to 4 factors (22.1% vs 13.1%; P < .001) but was comparable among patients with 0 or 1 factor (23.2% vs 20.4%; P = .62). We propose that CMV prophylaxis should be determined based on reactivation risk, as well as these other factors.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kaito S, Nakajima Y, Hara K, et al. Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation. Blood Adv. 2020. PMID: 32191806. doi:10.1182/bloodadvances.2019000814

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。